Covered recipient · General Payments record
WILLIAM P WERSCHLER
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$180,780.39
243 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $90,775.00 | 23 |
| Consulting Fee | $51,008.35 | 14 |
| Travel and Lodging | $29,063.86 | 56 |
| Food and Beverage | $6,175.89 | 148 |
| Honoraria | $3,750.00 | 1 |
| Education | $7.29 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie, Inc. | $92,262.09 | 96 |
| Merz North America, Inc. | $53,084.88 | 44 |
| PFIZER INC. | $12,710.32 | 12 |
| DERMIRA, INC. | $9,631.96 | 9 |
| Allergan Inc. | $6,577.04 | 22 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $1,948.81 | 7 |
| UCB, Inc. | $1,808.50 | 7 |
| Celgene Corporation | $1,354.56 | 6 |
| Aclaris Therapeutics, Inc. | $500.00 | 1 |
| Novartis Pharmaceuticals Corporation | $297.73 | 9 |
| Lilly USA, LLC | $95.64 | 3 |
| Sun Pharmaceutical Industries Inc. | $95.27 | 3 |
| Amgen Inc. | $78.95 | 4 |
| Galderma Laboratories, L.P. | $66.79 | 4 |
| Biofrontera Inc. | $41.12 | 2 |
| Janssen Scientific Affairs, LLC | $35.46 | 2 |
| GENZYME CORPORATION | $31.11 | 1 |
| Genentech USA, Inc. | $28.70 | 2 |
| LEO Pharma Inc. | $26.11 | 1 |
| Endo Pharmaceuticals Inc. | $22.43 | 1 |
| Merck Sharp & Dohme Corporation | $22.03 | 2 |
| PruGen, Inc. Pharmaceuticals | $22.03 | 3 |
| Regeneron Healthcare Solutions, Inc. | $21.24 | 1 |
| SANOFI-AVENTIS U.S. LLC | $17.62 | 1 |
Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WILLIAM P WERSCHLER
NPI 1023119682 · CMS profile ID 182368
Allopathic & Osteopathic Physicians / Dermatology
SPOKANE, WA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1023119682?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WILLIAM P WERSCHLER, NPI 1023119682, CMS profile ID 182368. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023119682?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). WILLIAM P WERSCHLER, NPI 1023119682, CMS profile ID 182368. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023119682?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- WILLIAM P WERSCHLER, NPI 1023119682, CMS profile ID 182368, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1023119682?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
243 matching records · $180,780.39 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 243.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie, Inc. | $265.07 | 05/02/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699197 | CMS |
| AbbVie, Inc. | $125.00 | 05/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699207 | CMS |
| GENZYME CORPORATION | $31.11 | 05/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694052013 | CMS |
| AbbVie, Inc. | $60.00 | 04/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699065 | CMS |
| Celgene Corporation | $20.49 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672776921 | CMS |
| Allergan Inc. | $700.00 | 04/16/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671300565 | CMS |
| Novartis Pharmaceuticals Corporation | $68.08 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660202059 | CMS |
| PFIZER INC. | $854.45 | 04/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673118509 | CMS |
| PFIZER INC. | $3,275.00 | 04/16/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673119333 | CMS |
| Amgen Inc. | $14.89 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663182233 | CMS |
| PFIZER INC. | $36.99 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673116393 | CMS |
| AbbVie, Inc. | $18.20 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699063 | CMS |
| Merz North America, Inc. | $984.97 | 04/03/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 689347635 | CMS |
| AbbVie, Inc. | $4,025.00 | 04/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699053 | CMS |
| AbbVie, Inc. | $4,025.00 | 04/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699221 | CMS |
| AbbVie, Inc. | $16.22 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699055 | CMS |
| AbbVie, Inc. | $383.13 | 03/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699059 | CMS |
| AbbVie, Inc. | $136.09 | 03/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699219 | CMS |
| AbbVie, Inc. | $181.93 | 03/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699223 | CMS |
| AbbVie, Inc. | $289.28 | 03/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699057 | CMS |
| DERMIRA, INC. | $2,800.00 | 03/27/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703884549 | CMS |
| Celgene Corporation | $3.74 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672757335 | CMS |
| AbbVie, Inc. | $19.74 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699061 | CMS |
| PFIZER INC. | $1,036.69 | 03/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673119961 | CMS |
| PFIZER INC. | $3,275.00 | 03/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673131815 | CMS |
| PFIZER INC. | $56.52 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673119441 | CMS |
| PFIZER INC. | $728.04 | 03/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673118411 | CMS |
| Genentech USA, Inc. | $12.94 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681237043 | CMS |
| PFIZER INC. | $3,275.00 | 03/11/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673119415 | CMS |
| Galderma Laboratories, L.P. | $13.18 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687726813 | CMS |
| PFIZER INC. | $117.29 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673120521 | CMS |
| Merz North America, Inc. | $20.88 | 03/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 689372325 | CMS |
| Merz North America, Inc. | $288.16 | 03/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 689373353 | CMS |
| Allergan Inc. | $22.13 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671300559 | CMS |
| Allergan Inc. | $150.00 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671300561 | CMS |
| Celgene Corporation | $17.30 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672739443 | CMS |
| Allergan Inc. | $41.67 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671300539 | CMS |
| Allergan Inc. | $139.75 | 02/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671300543 | CMS |
| Allergan Inc. | $412.67 | 02/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671300546 | CMS |
| Allergan Inc. | $92.30 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671300549 | CMS |
| Allergan Inc. | $3,990.00 | 02/28/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671300553 | CMS |
| Allergan Inc. | $76.42 | 02/28/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671300555 | CMS |
| PFIZER INC. | $18.93 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673119255 | CMS |
| Lilly USA, LLC | $16.50 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658223767 | CMS |
| AbbVie, Inc. | $18.18 | 02/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699049 | CMS |
| AbbVie, Inc. | $14.90 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699047 | CMS |
| Allergan Inc. | $1.09 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671300537 | CMS |
| Allergan Inc. | $7.47 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671300533 | CMS |
| UCB, Inc. | $1,680.00 | 02/11/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688235787 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $1,800.00 | 02/08/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684609729 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $202,255.36 | 81 |
| PY2024 | Principal investigator | $535,642.69 | 178 |
| PY2023 | Recipient | $2.02 | 1 |
| PY2023 | Principal investigator | $1,097,653.10 | 181 |
| PY2022 | Recipient | $7,404.27 | 2 |
| PY2022 | Principal investigator | $773,068.07 | 88 |
| PY2021 | Recipient | $4,157.88 | 3 |
| PY2021 | Principal investigator | $434,980.59 | 73 |
| PY2020 | Recipient | $47,971.91 | 14 |
| PY2020 | Principal investigator | $485,111.76 | 143 |
| PY2019 | Recipient | $27,873.36 | 39 |
| PY2019 | Principal investigator | $647,154.43 | 143 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
81 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $1,627.00 | 12/25/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175333020 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,601.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175332977 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 12/18/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202531318 |
| Principal investigator 1 | ABBVIE INC. | $1,178.70 | 12/04/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202528774 |
| Principal investigator 1 | ABBVIE INC. | $2,725.00 | 11/06/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202523261 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $16,151.25 | 11/06/2025 | Non-covered Recipient Entity Premier Clinical Research | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235994559 |
| Principal investigator 1 | ABBVIE INC. | $2,800.00 | 11/05/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202521855 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,495.00 | 11/03/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333044 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,072.00 | 10/31/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175333011 |
| Principal investigator 1 | Incyte Corporation | $1,696.50 | 10/22/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240577589 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,072.00 | 09/29/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175332959 |
| Principal investigator 1 | Incyte Corporation | $95.70 | 09/18/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577493 |
| Principal investigator 1 | Incyte Corporation | $1,187.00 | 09/18/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577499 |
| Principal investigator 1 | ABBVIE INC. | $1,985.25 | 09/04/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202508982 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,627.00 | 09/04/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175332991 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,175.00 | 08/25/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333094 |
| Principal investigator 1 | Incyte Corporation | $861.30 | 08/21/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577487 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,913.00 | 08/01/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175332997 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,627.00 | 07/28/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175332984 |
| Principal investigator 1 | ABBVIE INC. | $148.50 | 07/17/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202498750 |
| Principal investigator 1 | ABBVIE INC. | $3,400.00 | 07/10/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | Multicenter Double-Blind Randomized Placebo-controlled Dose-Ranging Phase 2 Active Comparator Study Evaluating the Efficacy and Safety of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines | No dispute reported | 06/30/2026 | 1202497796 |
| Principal investigator 1 | ABBVIE INC. | $2,628.60 | 07/08/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497390 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,913.00 | 06/27/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333029 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $2,400.00 | 06/25/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232945578 |
| Principal investigator 1 | Eli Lilly and Company | $4,452.10 | 06/05/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187889482 |
| Principal investigator 1 | ABBVIE INC. | $2,731.20 | 06/03/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202487617 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 06/02/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240577565 |
| Principal investigator 1 | Incyte Corporation | $250.00 | 06/02/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240577571 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 06/02/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240577577 |
| Principal investigator 1 | Incyte Corporation | $550.00 | 06/02/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240577583 |
| Principal investigator 1 | ABBVIE INC. | $3,817.20 | 05/28/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 1202486415 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,948.00 | 05/26/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333050 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,480.00 | 05/22/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175332966 |
| Principal investigator 1 | ABBVIE INC. | $1,314.30 | 05/07/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202483253 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,480.00 | 04/28/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175333058 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $2,900.00 | 04/23/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232945242 |
| Principal investigator 1 | ABBVIE INC. | $379.35 | 04/17/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202477405 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,926.00 | 04/14/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175332972 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 04/08/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577541 |
| Principal investigator 1 | Incyte Corporation | $6,600.00 | 04/08/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577548 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 04/08/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577553 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 04/08/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577560 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,830.00 | 04/07/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175333067 |
| Principal investigator 1 | ABBVIE INC. | $2,812.20 | 04/03/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202470584 |
| Principal investigator 1 | Janssen Research & Development, LLC | $415.00 | 03/31/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175333006 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $63.40 | 03/25/2025 | Non-covered Recipient Entity Premier Clinical Research | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235994563 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 03/24/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240577505 |
| Principal investigator 1 | Incyte Corporation | $10.00 | 03/24/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240577517 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,392.00 | 03/24/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333101 |
| Principal investigator 1 | Eli Lilly and Company | $11,375.80 | 03/18/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 1187887994 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,350.00 | 03/14/2025 | Non-covered Recipient Entity Premier Clinical Research | A multi-centre, multi-national clinical study to evaluate the safety and effectiveness of the Essure (Model ESS505) device to prevent pregnancy in women who are seeking permanent contraception | No dispute reported | 06/30/2026 | 1225411760 |
| Principal investigator 1 | ABBVIE INC. | $1,365.60 | 03/07/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202459668 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,014.00 | 03/03/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175333085 |
| Principal investigator 1 | Incyte Corporation | $49.66 | 02/24/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240577530 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,400.00 | 02/12/2025 | Non-covered Recipient Entity Premier Clinical Research | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235994565 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,011.00 | 02/07/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333036 |
| Principal investigator 1 | ABBVIE INC. | $2,115.00 | 02/06/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202446988 |
| Principal investigator 1 | Incyte Corporation | $0.98 | 02/06/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553866 |
| Principal investigator 1 | Incyte Corporation | $1.96 | 02/06/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553871 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,014.00 | 01/24/2025 | Non-covered Recipient Entity PREMIER CLINCIAL RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175333074 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $2,900.00 | 01/22/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232944614 |
| Principal investigator 1 | Incyte Corporation | $79.65 | 01/21/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577595 |
| Principal investigator 1 | Incyte Corporation | $24.97 | 01/21/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577602 |
| Principal investigator 1 | Incyte Corporation | $323.00 | 01/21/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577631 |
| Principal investigator 1 | Incyte Corporation | $74.00 | 01/17/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577607 |
| Principal investigator 1 | Incyte Corporation | $74.00 | 01/17/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577615 |
| Principal investigator 1 | Incyte Corporation | $23.92 | 01/17/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577621 |
| Principal investigator 1 | Incyte Corporation | $148.00 | 01/17/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240577627 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $7,850.00 | 01/16/2025 | Non-covered Recipient Entity Premier Clinical Research | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235994561 |
| Principal investigator 1 | Incyte Corporation | $1,634.00 | 01/10/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240577535 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 01/09/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202437406 |
| Principal investigator 1 | Incyte Corporation | $10.00 | 01/06/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240577512 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 01/06/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240577523 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $37,040.15 | 01/03/2025 | Non-covered Recipient Entity Premier Clinical Research | A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1235994567 |
| Principal investigator 1 | ABBVIE INC. | $152.55 | 01/02/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202433555 |
| Principal investigator 1 | ABBVIE INC. | $2,812.20 | 01/02/2025 | Non-covered Recipient Entity PREMIER CLINICAL RESEARCH LLC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202433559 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553840 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553844 |
| Principal investigator 1 | Incyte Corporation | $3.96 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553849 |
| Principal investigator 1 | Incyte Corporation | $7.08 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553857 |
| Principal investigator 1 | Incyte Corporation | $61.70 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553861 |